Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 7

Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

April 16, 2025

Caron A. Jacobson, MD, MMSc, Peter Riedell, MD

Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: CAR-T in Second-Line DLBCL: When and for Whom?

EP. 2: Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024

EP. 3: CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

EP. 4: Guiding Patients Through CAR T: Key Discussion Points

EP. 5: Future Directions for CAR T-Cell Therapy in LBCL: What’s Next?

EP. 6: Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies

Now Viewing

EP. 7: Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

EP. 8: CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

EP. 9: Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

EP. 10: Key Takeaways: CAR T in Real-World Clinical Practice

Video content above is prompted by the following: